Application of electric fields to the lung as therapy for pulmonary edema

• US 8,634,906 B2
• Filed: 12/31/2012
• Issued: 01/21/2014
• Est. Priority Date: 05/07/2009
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Wariar, Ramesh
• Primary Examiner(s): Holmes, Rex R
• Application Number:
  US13/731,812
• Publication Number:
  US 20130123878A1
• Time in Patent Office: 386 Days
• Field of Search: 607/17, 607/36, 600/345, 600/529, 600/547
• US Class Current: 600/547
• CPC Class Codes: A61B 5/0537 Measuring body composition by impedance, e.g. tissue hydration or fat content
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61B 5/4878 Evaluating oedema
• CPC Class Codes: A61N 1/205 for promoting a biological process
• CPC Class Codes: A61N 1/32 alternating or intermittent currents applying electric fields by inductive or capacitive coupling A61N1/40; microwave apparatus A61N5/02
• CPC Class Codes: A61N 1/3601 of respiratory organs
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

System and method of applying electric fields to a patient'"'"'s lung(s) to reduce pulmonary edema. The system includes a first electrode and a second electrode, at least one of which is associated with the lung. The electric field can be controlled so as to modulate a level of fluid in the lung.

Claims

1. A device comprising:

an electric field generator circuit configured to generate an electric field for application to a lung of a subject, the electric field being capable of modulating a level of fluid in the lung; and

a controller coupled to the electric field generator circuit and configured to control the electric field in the lung so as to use the electric field to modulate the level of fluid in the lung, wherein the controller is configured to apply the electric field to alveolar cells of the lung at an electric field level that is of sufficient magnitude to controllably effect removal by the alveolar cells of the fluid from the lung.

2. The device of claim 1, wherein the controller is configured to control the electric field so as to modulate a level of fluid in the lung by modulating alveolar Na,K-ATPase activity.

3. The device of claim 1, comprising a cardiac signal sensing circuit configured to sense an intrinsic cardiac signal, wherein the controller is:

coupled to the sensing circuit and configured to determine an absolute cardiac refractory period; and

configured to control the electric field generator circuit to deliver pulses substantially only during the absolute cardiac refractory period.

4. The device of claim 1, comprising a fluid monitoring circuit configured to monitor a level of fluid in the lung, wherein the controller is configured to control the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.

5. The device of claim 1, wherein the electric field generator circuit is configured to generate an alternating electric field with field strength of about 5 microvolts/cm to about 50 millivolts/cm.

6. The device of claim 1, wherein the electric field generator circuit is configured to generate pulses at a frequency of about 1.0 MHz.

7. The device of claim 1, wherein the controller is configured to control at least one of a magnitude, a pulsewidth, a frequency, a duration, a duty cycle, or a waveform morphology associated with the electric field to control the level of fluid in the lung.

8. The device of claim 1, wherein the controller is configured to control the electric field in the lung using information from at least one implantable sensor including at least one of an implantable heart sound sensor, an implantable impedance sensor, an implantable physical activity sensor, an implantable respiration sensor, an implantable blood pressure sensor, an implantable electrocardiogram sensor, an implantable oxygen saturation sensor, an implantable blood flow sensor, or an implantable temperature sensor.

9. The device of claim 1, wherein the electric field generator circuit is configured to be coupled to a first electrode and a second electrode, wherein at least one of the first electrode or the second electrode is configured to be associated with the lung of the subject.

10. A method comprising:

generating and applying an electric field to a lung of a subject, the electric field being capable of modulating a level of fluid in the lung; and

controlling the electric field to modulate the level of fluid in the lung, wherein controlling the electric field includes applying the electric field to alveolar cells of the lung at an electric field level that is of sufficient magnitude to modulate alveolar Na,K-ATPase activity to controllably effect removal by alveolar cells of the fluid from the lung.

11. The method of claim 10, comprising:

sensing an intrinsic cardiac signal;

determining an absolute cardiac refractory period; and

delivering electric pulses substantially only during the absolute cardiac refractory period.

12. The method of claim 10, comprising monitoring a level of fluid in the lung, wherein the controlling the electric field includes controlling the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.

13. The method of claim 10, wherein applying an electric field includes providing an alternating electric field with field strength of about 5 microvolts/cm to about 50 millivolts/cm.

14. The method of claim 10, wherein the applying an electric field includes providing pulses at a frequency of about 1.0 MHz.

15. The method of claim 10, wherein the controlling the electric field includes controlling at least one of a magnitude, a pulsewidth, a frequency, a duration, a duty cycle, or a waveform associated with the electric field to control the level of fluid in the lung.

16. The method of claim 10, wherein applying the electric field to the subject includes applying the electric field using a first electrode and a second electrode, at least one of the first electrode or the second electrode being associated with a lung of the subject.

17. The method of claim 16, wherein applying the electric field includes using the first electrode and the second electrode in or near at least one of a lung, a heart, a thoracic vein, a thoracic artery, or a thoracic lymph node.

18. A device-readable medium including instructions that, when performed by a device, cause the device to perform acts comprising:

generating and applying an electric field to a lung of a subject, the electric field being capable of modulating a level of fluid in the lung; and

controlling the electric field to modulate the level of fluid in the lung, wherein controlling the electric field includes applying the electric field to alveolar cells of the lung at an electric field level that is of sufficient magnitude to modulate Na,K-ATPase activity to controllably effect removal by alveolar cells of the fluid from the lung.

19. The device-readable medium of claim 18, including instructions that, when performed by the device, cause the device to perform acts comprising:

sensing an intrinsic cardiac signal;

determining an absolute cardiac refractory period; and

delivering electric pulses substantially only during the absolute cardiac refractory period.

20. The device-readable medium of claim 18, including instructions that, when performed by the device, cause the device to perform acts comprising monitoring a level of fluid in the lung, wherein the controlling the electric field includes controlling the electric field using information about the monitored level of fluid in the lung to control the level of fluid in the lung.